Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Pulmonary fibrosis is a sequela of severe infection COVID-19.The prevalence of PCFP ranged
from 2% to 45%,and the pathogenesis of PCFP has not been clearly elucidated.The ingredient of
Bailing capsule is Cs-C-Q80,it has obvious protective effect on lung.
Studies have shown that Bailing capsule may improve the clinical symptoms of PCPF patients
through anti-fibrosis, oxidation and anti-inflammatory effects in multiple pathways.
The purpose of this study was to evaluate the efficacy and safety of bailing capsule in
treating PCFP after COVID-19 infection.
Phase:
N/A
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University